The incidence of AKI was practically similar in the groups of anti-PD-1 (5.32%) and anti-PD-L1 (5.25%) but increased in patients treated with anti-CTLA-4 drugs (7.83%). The gene discussed is PDCD1; the disease is acute kidney injury.